Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment

This phase 3 trial compared the efficacy and safety of once weekly insulin efsitora with once daily insulin degludec in 928 adults with type 2 diabetes who had not previously received insulin. Over 52 weeks, efsitora demonstrated noninferiority to degludec in reducing glycated hemoglobin levels (mean change: 1.26% vs. 1.17%; treatment difference: 0.09%, 95% CI: 0.22 to 0.04). Efsitora also showed comparable time in target glucose range (64.3% vs. 61.2%) and similar rates of hypoglycemia (0.58 vs. 0.45 events per participant year), with no severe hypoglycemia reported in the efsitora group. The study concluded that once weekly efsitora is a viable alternative to daily degludec, offering simplified dosing without compromising efficacy or safety.

This phase 3 trial compared the efficacy and safety of once weekly insulin efsitora with once daily insulin degludec in 928 adults with type 2 diabetes who had not previously received insulin. Over 52 weeks, efsitora demonstrated noninferiority to degludec in reducing glycated hemoglobin levels (mean change: 1.26% vs. 1.17%; treatment difference: 0.09%, 95% CI: 0.22 to 0.04). Efsitora also showed comparable time in target glucose range (64.3% vs. 61.2%) and similar rates of hypoglycemia (0.58 vs. 0.45 events per participant year), with no severe hypoglycemia reported in the efsitora group. The study concluded that once weekly efsitora is a viable alternative to daily degludec, offering simplified dosing without compromising efficacy or safety.